Regencell Bioscience (RGC) vs Trulieve Cannabis Subordinate Voting Shares (TRLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trulieve Cannabis Subordinate Voting Shares (TRLV) has outperformed Regencell Bioscience (RGC) over the past year, gaining 18.0% versus a loss of 60.7%. Over five years, RGC leads with a +1455.6% price change compared with -60.5% for TRLV. Regencell Bioscience is the larger company by market cap ($3.78 billion vs $2.00 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGC | TRLV |
|---|---|---|
| Share price | $7.63 | $10.37 |
| Market cap | $3.78B | $2.00B |
| 1-day change | +7.31% | -3.80% |
| YTD return | -63.67% | +19.33% |
| 1-year return | -60.67% | +17.97% |
| 5-year return | +1455.56% | -60.45% |
| Forward P/E | — | 18.63 |
| EPS (TTM) | $-0.02 | $-2.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.18B |
| Revenue growth (YoY) | — | -0.45% |
| Net income (latest FY) | $-11.70M | $-122.25M |
| Gross margin | — | 60.21% |
| Operating margin | — | 12.15% |
| Net margin | — | -10.35% |
| 52-week high | $69.00 | $13.28 |
| 52-week low | $4.51 | $4.62 |
| Distance from 52-week high | -88.94% | -21.91% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +75.31% |
| Average volume | 199.19K | 1.61M |
| Shares outstanding | 495.88M | 170.16M |
| Employees | 10 | 5,000 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRLV has outperformed RGC by 78.6 percentage points over the past year.
About Regencell Bioscience
RGC stock →Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 10 employees
About Trulieve Cannabis Subordinate Voting Shares
TRLV stock →Trulieve Cannabis Corp. operates as a cannabis retailer in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 5,000 employees
RGC vs TRLV FAQ
Which is bigger, Regencell Bioscience or Trulieve Cannabis Subordinate Voting Shares?
Regencell Bioscience (RGC) is larger, with a market capitalization of $3.78B compared with $2.00B for Trulieve Cannabis Subordinate Voting Shares (TRLV).
Which stock has performed better over the past year, RGC or TRLV?
TRLV returned +17.97% over the past 12 months, compared with -60.67% for RGC (price return, excluding dividends). Past performance does not predict future results.
Are Regencell Bioscience and Trulieve Cannabis Subordinate Voting Shares in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.